NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMAS

Clinical trials for NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMAS explained in plain language.

Never miss a new study

Get alerted when new NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMAS trials appear

Sign up with your email to follow new studies for NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMAS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Last-Resort drug access opens for rare tumor patients

Disease control AVAILABLE

This program provides mirdametinib to individual patients with severe, life-threatening conditions like NF1-related tumors or MAP-K pathway diseases who have no other treatment options and cannot join a clinical trial. Each case requires approval from the company, ethics board, a…

Matched conditions: NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMAS

Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany • Aim: Disease control

Last updated May 14, 2026 12:06 UTC

NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMAS

Get alerted when new NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMAS trials appear

Last-Resort drug access opens for rare tumor patients